Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1864MR)

This product GTTS-WQ1864MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1864MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11443MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ923MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ10521MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ3161MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ342MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 1F5
GTTS-WQ10300MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ15246MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA TAK-079
GTTS-WQ11974MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MM-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW